Gilead Sciences stock nears its all-time high
Gilead Sciences stock nears its all-time high: buy or sell?
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million settlement with American authorities. It has risen for two consecutive weeks,
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Why Gilead Sciences Stock Thrashed the Market Today
There was some good news in the clinical sphere for Gilead Sciences (NASDAQ: GILD) on Thursday, and this drove its stock price up by almost 3% that trading session. A late-stage clinical trial of an investigational drug yielded encouraging initial results, hence the rise. In comparison, the S&P 500 index inched up by 0.8% on the day.
Gilead Sciences Inc. stock rises Thursday, still underperforms market
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Why Is Gilead Sciences, Inc. (GILD) Stock Surpassing 9.90% from Its 50-Day SMA?
Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $81.44 which represents a slight increase of $2.27 or 2.87% from the prior close of $79.17. The stock opened at $79.17 and touched a low of $78.
Gilead Sciences Unusual Options Activity For September 20
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...
Seeking Alpha20d
Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices
But we should not assume that Gilead Sciences’ stock price will not be affected by a steep bear market. Most likely it will decline as well – but maybe the decline is less steep and maybe the ...
Yahoo Finance9d
Gilead Sciences, Inc. (GILD)
Twice-yearly lenacapavir also demonstrated sup Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study. Gilead Sciences ...
Wall Street Journal5d
Gilead Sciences Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing ...
Seeking Alpha22d
Gilead Sciences: Buy This Bargain Before It's Gone
Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of ...
Hold Rating on Gilead Sciences Amid Lenacapavir’s Promise and Market Uncertainties
Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...